Irbesartan + Hidroclorotiazida Generis

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Generis, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension by lowering blood pressure in adult patients. GNH USA supplies Irbesartan + Hidroclorotiazida Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is indicated for the management of elevated blood pressure within the antihypertensive drug class. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Essential hypertension: improves blood pressure control when monotherapy is insufficient. - High blood pressure in adults: provides combined vasodilation and diuretic effects for better therapeutic outcomes.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia or severe low potassium - Angioedema or swelling of face, lips, tongue - Significant hypotension leading to fainting - Allergic reactions such as rash or hives

Patients should be monitored regularly for blood pressure, renal function, and electrolyte levels. - Monitor blood pressure: ensure therapeutic targets are reached without excessive lowering. - Assess renal function: check creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium and sodium levels. - Avoid use in pregnancy: drug is classified as Category D and may harm the fetus. - Use caution in elderly: increased sensitivity to blood pressure changes. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medications. Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - NSAIDs (high dose): can reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations. - Other antihypertensives: may cause additive blood pressure lowering. - Antidiabetic drugs: diuretic effect may affect glucose control. - Anticoagulants: diuretic‑induced volume changes may alter drug levels. - Thiazide‑sensitive drugs (e.g., digoxin): monitor for toxicity due to electrolyte shifts.